Meda acquires product portfolio from the US pharma company Wyeth

Meda acquires product portfolio from the US pharma company Wyeth

•	Meda is acquiring 10 well-established pharmaceutical products from Wyeth


•	The products give Meda sales of about SEK 160-170 million for the remainder of
2007 (8 months)


•	Meda's position is strengthened on key European markets such as Italy and
France


•	The purchase price is about SEK 525 million

Meda and the US pharma company Wyeth have reached an agreement regarding
acquisition of 10 well-established pharmaceuticals in Europe.  The agreement
with Wyeth is one example of how we use our strong platform throughout Europe
for profitable, marginal deals,” says Anders Lönner, Meda's CEO.

The acquired products are highly recognised brands with good profitability. The
effective date is 1 May 2007. No employees will transfer from Wyeth to Meda in
conjunction with the acquisition, which is expected to inject sales of about SEK
160-170 million into Meda's operation for the remainder of 2007. The purchase
price is about SEK 525 million, which will be totally financed via existing
credit facilities.

Through the acquisition, Meda strengthens its position on two of its most
important markets Italy and France. These countries account for about 60% of the
acquired products' sales.

The largest acquired product is Seresta®, a central nervous system (CNS) drug
with the active substance oxazepam. Oxazepam belongs to the benzodiazepine group
of drugs and is an anti-anxiety agent used for sleep disorders and various
substance-withdrawal syndromes. Meda already has three major CNS products:
Imovane® (sleep disorders), Thiocticacid® (diabetic neuropathy), and Parlodel®
(Parkinson's disease).
The majority of sales come from these acquired products:
See attached file.


For more information, please contact:
Anders Lönner, CEO		         tel. +46 8 630 19 72
Anders Larnholt, Investor Relations	tel. +46 8 630 19 62, +46 709 458 878


MEDA AB (publ) is a leading European specialty pharma company that concentrates
on marketing and marketadapted product development. Acquisitions and long-term
partnerships are fundamental factors that drive the company's strategy. Meda has
own affiliates in 24 countries and more than 1,000 employees within marketing
and sales. The Meda share is listed under Large Cap on the OMX Nordic Stock
Exchange. Find out more, visit www.meda.se.